On Thursday, November 12, 2015, DelMar Pharmaceuticals Inc. ($DMPI) will present at the SeeThruEquity Microcap Investor Forum at 10:00 a.m. EST. DelMar’s CFO Scott Praill will present a corporate overview and provide an update on the ongoing Phase II clinical trial of VAL-083, a groundbreaking anti-cancer drug, in patients with recurrent glioblastoma multiforme (GBM). Praill will also discuss the company's plans to initiate clinical trials with VAL-083 as a potential treatment for non-small cell lung cancer(NSCLC) and the promising potential of VAL-083 as chemotherapeutic alternative in ovarian cancer, pediatric brain tumorsand other solid tumors.
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. Their conferences, featuring 30-minute presentations by the company management’s teams and 1-on-1 meetings with scheduled investors, allow presenting company management teams access to industry professionals and investors.This year,the conference will take place at the Convene Grand Central in New York City.
DelMar’s Recent Achievements in Fight Against Cancer
A biopharmaceutical company focused on the development and commercialization of new cancer therapies, DelMar Pharmaceutical’s first-in-class, small-molecule chemotherapeutic, VAL-083, is currently undergoing clinical trials in the US VAL-083 has been extensively studied by US National Cancer Institute. Currently, VAL-083 is used in China as treatment for of chronic myelogenous leukemia and lung cancer.
DelMar recently completed enrollment in the Phase II expansion cohort of the study and confirmed 40mg/m2 as the maximum tolerated dose (MTD) for advancement into registration-directed Phase II/III clinical trials in GBM. Patients have been enrolled at five clinical centers in the United States: Mayo Clinic, UCSF, and three centers associated with the Sarah Cannon Cancer Research Institute.
In the fight against cancer, DelMar continues to make positive strides with their innovative anti-cancer research and clinical trials. Through informative forums and promising networking opportunities, DelMar is one step closer to bringing VAL-083 to patients in need.
Equities.com had the opportunity to interview Jeffrey Bacha, President and CEO of DelMar Pharmaceuticals. The interview can be watched here. For more information about DelMar Pharmaceuticals, visit www.delmarpharma.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer